Alto Neuroscience (ANRO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Mar, 2026Executive summary
Annual meeting scheduled for May 12, 2026, with virtual attendance available for shareholders of record as of March 16, 2026.
Shareholders are encouraged to review proxy materials online before voting and can request paper or email copies if desired.
Voting matters and shareholder proposals
Election of two Class II Director nominees, Raymond Sanchez, M.D. and Gwill York, to serve until the 2029 Annual Meeting.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Approval of amendments to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan to treat pre-funded warrants as outstanding shares for share reserve calculations under the "evergreen" feature.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals presented.
Latest events from Alto Neuroscience
- ALTO-207 demonstrates robust efficacy in TRD, with late-stage trials and major catalysts ahead.ANRO
Bank of America Global Healthcare Conference 202614 May 2026 - Biomarker-driven pipeline advances novel, personalized treatments for mental health disorders.ANRO
Corporate presentation13 May 2026 - Q1 2026 net loss rose to $26.2M as R&D spending increased; cash reserves reached $264.3M.ANRO
Q1 202613 May 2026 - 6 million shares registered for resale after $120M private placement; no proceeds to company.ANRO
Registration filing10 Apr 2026 - Biomarker-guided neuropsychiatric pipeline targets major unmet needs with late-stage trials ahead.ANRO
Corporate presentation2 Apr 2026 - Shareholders will vote on director elections, auditor ratification, and key equity plan amendments.ANRO
Proxy filing26 Mar 2026 - ALTO-207 advances in TRD with rapid titration, strong efficacy, and key pipeline catalysts ahead.ANRO
Stifel 2026 Virtual CNS Forum17 Mar 2026 - Biomarker-driven CNS drug portfolio advances multiple late-stage trials with strong financial runway.ANRO
Corporate presentation16 Mar 2026 - ALTO-207 acquisition and robust cash support multiple pivotal trials through 2028.ANRO
Q4 202516 Mar 2026